Britain's health technology assessment body, NICE, has approved two diagnostic tests for endometriosis to be used in the NHS in England and Wales. The announcement came July 7, 2026, but with a condition: these tests will be monitored for three years while doctors gather more data before deciding whether to keep them permanently Guardian.

The two tests work in completely different ways. Endotest analyzes a saliva sample sent to a lab, looking for tiny fragments of genetic material called microRNA that are linked to endometriosis. Early studies show it catches the disease correctly more than 95% of the time Medscape. EndoSure, by contrast, uses small sensor pads placed on the skin of the lower belly to measure electrical activity in the gut — activity that changes when endometriosis has caused scar tissue and lesions in the pelvis. It gives a result in just 45 minutes Guardian. A third test called DotEndo didn't make the cut; NICE said the evidence for it isn't ready yet.

NICE has been careful about how these tests fit into diagnosis. They're not meant to replace the gold standard — a diagnostic procedure called laparoscopy, where a surgeon looks directly inside the pelvis with a camera — or standard imaging scans. Instead, NICE has restricted their use to women whose symptoms suggest endometriosis, whose basic pelvic exam was normal, and whose imaging scans (usually ultrasound or MRI) came back negative or unclear. In practice, this means the tests function as a second checkpoint in the diagnostic chain, used in GP surgeries and hospitals once initial screening hasn't settled the matter.

Why do these tests matter? Endometriosis is notoriously difficult to pin down. The average woman in Britain waits nine years and four months from her first symptoms to a confirmed diagnosis Guardian. That long delay reflects several realities: people often normalize pelvic pain, the NHS doesn't have enough gynaecologists, and until now, confirmation has required laparoscopy — an invasive operation that comes with its own waiting list.

Many doctors have welcomed the move. A consultant gynaecologist at Manchester University NHS Foundation Trust called the tests a "gamechanger," and Endometriosis UK hailed them as non-invasive tools that could speed up diagnosis in NHS clinics NICE.

The three-year trial window is NICE's standard approach for new technologies that show promise but don't yet have enough real-world evidence behind them. During this period, the health service will track how accurately these tests actually perform across different NHS settings, whether they lead to the right follow-up decisions, and whether they save money overall. Only then will NICE decide whether to keep recommending them.

Here's what remains uncertain. A 95% accuracy figure is impressive on paper, but laboratory results often tell a different story once a test is rolled out across busy clinics and GP practices with different equipment, staff training, and patient populations. The three-year evaluation is specifically designed to catch any gap between the controlled trial setting and the messy reality of the NHS.

There's a broader structural issue worth watching. Faster diagnosis is only half the solution. These tests don't speed up access to the gynaecologists, surgery, or pain management that follow diagnosis. If the NHS can now identify endometriosis faster but can't quickly treat it, the bottleneck simply shifts downstream rather than disappearing. NICE and NHS planners will need to track this carefully over the next three years alongside the accuracy data.